Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-sirolimus in Solid Tumors with TSC1 or TSC2 Alterations
NCT05103358Phase 2Completed
- Sponsor
- Aadi Bioscience, Inc.
- Start
- Mar 2022
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of nab-sirolimus in solid tumor, sponsored by Aadi Bioscience, Inc.. Started Mar 2022; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05103358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103358.